Tofacitinib for the Treatment of Tumor Necrosis Factor-α Inhibitor Refractory Esophageal Crohn's Disease

A Case Report

Sunina Nathoo; William A. Hood; Sara Keihanian; Amy L. Collinsworth; Sarah C. Glover


J Med Case Reports. 2016;10(264) 

In This Article


Esophageal CD may be a difficult diagnosis to obtain and requires a crossroads between clinical, endoscopic, histological, and radiographic data. This case highlights the use of tofacitinib as an alternative therapy for patients with esophageal CD, and should be a consideration especially in patients who do not benefit from TNF-α inhibitor use. This case also highlights the ability of patients to develop esophageal CD during TNF-α inhibitor therapy, a phenomenon previously described in the literature.[5]